Bridge Biotherapeutics, Inc.
Sujin JUNG has extensive experience in the pharmaceutical industry, with a focus on clinical development, regulatory operations, and medical affairs. Sujin has held various leadership roles at companies like Bridge Biotherapeutics, Odonate Therapeutics™, and Eli Lilly and Company, where Sujin has managed clinical trials, regulatory submissions, and site activation processes. Sujin has also worked as a training instructor at Pusan National University and as a pharmacist at Samsung Medical Center. Sujin holds a Bachelor's degree in Pharmacy, a Master's degree in Pharmaceutical Outcomes research from Chung-Ang University, and is currently pursuing a Global Clinical Scholars Research Training degree at Harvard Medical School.
This person is not in any offices
Bridge Biotherapeutics, Inc.
Bridge Biotherapeutics, Inc. is a virtually-operated, venture-backed clinical stage global biotech company, headquartered in Seongnam, Korea with its subsidiary at JLABS@TMC, engaged in the development of novel therapeutics, focusing on therapeutic areas of high unmet medical needs, such as ulcerative colitis, fibrotic diseases, and cancers.